CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH has a total of 13 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2015. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Mexico. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are IMMPORT THERAPEUTICS INC, CELCUITY INC and CEMM FORSCHUNGSZENTRUM FUR MOLEKULARE MEDIZIN GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | Mexico | 1 | |
#4 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials | |
#4 | Microorganisms | |
#5 | Peptides | |
#6 | Microbiology | |
#7 | Heterocyclic compounds | |
#8 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Superti-Furga Giulio | 4 |
#2 | Huber Kilian | 4 |
#3 | Kubicek Stefan | 3 |
#4 | Vladimer Gregory | 2 |
#5 | Licciardello Marco | 2 |
#6 | Snijder Berend | 2 |
#7 | Vladimer Gregory Ian | 1 |
#8 | Stefan Kubicek | 1 |
#9 | Jin Li | 1 |
#10 | Krall Nikolaus | 1 |
Publication | Filing date | Title |
---|---|---|
EP3285753A1 | Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer | |
WO2016135138A1 | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer | |
WO2016135139A1 | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer | |
WO2016135137A1 | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer | |
WO2016135140A1 | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer | |
EP3227341A1 | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies | |
US2017356911A1 | Monolayer of pbmcs or bone-marrow cells and uses thereof | |
EP3143143A1 | Antagonists of slc38a9 and their use in therapy |